Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 18 Oct 2017 Status changed from completed to discontinued.
- 02 Mar 2017 Status changed from active, no longer recruiting to completed.
- 06 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.